Cologuard Plus
The updated Cologuard, approved in 2024, which keeps the high cancer detection rate while causing fewer false alarms.
Overview
Cologuard Plus was approved by the FDA in October 2024 and launched in 2025. In the BLUE-C study (NEJM 2024, more than 20,000 participants) sensitivity for colorectal cancer was 93.9% versus 67.3% for FIT, sensitivity for advanced precancerous lesions was 43.4% versus 23.3%, and specificity for advanced neoplasia was 90.6% versus 94.8%, a roughly 30% reduction in false positives compared with the original Cologuard. The test is used every three years in average-risk adults aged 45 and older. Exact Sciences, now being acquired by Abbott, positions it against blood tests such as Shield, whose sensitivity for precancerous polyps is much lower.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Colorectal cancer screening in average-risk adults aged 45 and older |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Notes
top- What a result means: the same as Cologuard, with fewer people sent for a colonoscopy they did not need.
Latest papers
topQuery for this drug: (TITLE:"Cologuard Plus" OR ABSTRACT:"Cologuard Plus") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cologuard Plus, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductCancerguard
Shares Exact Sciences (Abbott), Shield, Screening, DNA methylation profiling and the tag test.
- ProductOncodetect
Shares Exact Sciences (Abbott), Colorectal cancer and the tag test.
- ProductAfirma Genomic Sequencing Classifier
Shares Sensitivity and specificity and the tag test.
- ProductGuardant Reveal
Shares DNA methylation profiling, Colorectal cancer and the tag test.
- ProductMI Cancer Seek
Shares Colorectal cancer and the tag test.
- ProductTempus xT CDx
Shares Colorectal cancer and the tag test.
- ProductVENTANA MMR RxDx Panel
Shares Colorectal cancer and the tag test.
- Producttherascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)
Shares Colorectal cancer and the tag test.